Like many industries, the pharmaceutical labour market has felt and will continue to feel the impacts of the COVID-19 pandemic moving into 2023 and beyond.
As part of our Women in Pharma series, where we talk to leading figures in the life sciences, we hear from Şeyda Atadan Memiş, recently appointed general manager for Takeda UK and
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<
